Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1.

Journal of diabetes research - 1 Jan 2016

Sedman Tuuli, Rünkorg Kertu, Krass Maarja, Luuk Hendrik, Plaas Mario, Vasar Eero, Volke Vallo

Abstract excerpt

Wolfram syndrome 1 is a very rare monogenic disease resulting in a complex of disorders including diabetes mellitus. Up to now, insulin has been used to treat these patients. Some of the monogenic forms of diabetes respond preferentially to sulphonylurea preparations. The aim of the current study was to elucidate whether exenatide, a GLP-1 receptor agonist, and glipizide, a sulphonylurea, are effective in a mouse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Blood Glucose
Share to Glucagon-Like Peptide-1 Receptor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypoglycemic Agents

Share to Insulin

Share to Mice, 129 Strain

Share to Peptides

Share to Wolfram Syndrome

Source

Open in PubMed Open full text

Identifiers

PMID: 27069934
DOI: 10.1155/2016/9239530
PMCID: PMC4812441

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1.PMID 27069934Read ↗

GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical modelsSemantic proximity Read ↗

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.Semantic proximity Read ↗

GLP-1 Receptor Agonist Improves Metabolic Disease in a Pre-clinical Model of LipodystrophySemantic proximity Read ↗

Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype.Semantic proximity Read ↗

GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor.Semantic proximity Read ↗

Evaluating the Use of GLP-1 Receptor Agonists in Wolfram syndrome PatientsSemantic proximity Read ↗

Early intervention and lifelong treatment with GLP1 receptor agonist liraglutide in a Wolfram Syndrome rat model with an emphasis on visual neurodegeneration, sensorineural hearing loss and diabetic phenotypeSemantic proximity Read ↗

Glucose homeostasis is impaired in mice deficient for the neuropeptide 26RFa (QRFP)Semantic proximity Read ↗

Prep1 deficiency induces protection from diabetes and increased insulin sensitivity through a p160-mediated mechanism.Semantic proximity Read ↗

Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice.Semantic proximity Read ↗

Wfs1 mutation makes mice sensitive to insulin-like effect of acute valproic acid and resistant to streptozocin.Semantic proximity Read ↗

The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.